October 09, 2019
William Kaelin named Nobel Prize winner
May 21, 2019
Merck to Acquire Peloton Therapeutics, Bolstering Oncology Pipeline
April 22, 2019
Turning Point Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
July 24, 2019
Kura Oncology’s Menin-MLL Inhibitor KO-539 Receives Orphan Drug Designation from FDA for Treatment of Acute Myeloid Leukemia
July 18, 2019
Blueprint Medicines Announces European Medicines Agency Validation of Marketing Authorization Application for Avapritinib for the Treatment of PDGFRα D842V Mutant GIST and Fourth-Line GIST
July 15, 2019
Neon Therapeutics’ Personal Neoantigen Vaccine Study Demonstrates Prolonged Progression-Free Survival in Advanced or Metastatic Melanoma, Non-Small Cell Lung and Bladder Cancers
July 09, 2019
IDEAYA Biosciences Strengthens Management with Internal Appointments of Paul Stone, J.D., as Chief Financial Officer, Andres Ruiz Briseno, C.P.A., as Vice President, Finance, and Mick O’Quigley, M.B.A, as Vice President, Development Operations
June 25, 2019
Arvinas Receives Authorization to Proceed for ARV-471, a PROTAC® Protein Degrader to Treat Patients with Locally Advanced or Metastatic ER+ / HER2- Breast Cancer
June 19, 2019
Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock
June 15, 2019
Blueprint Medicines Presents Updated EXPLORER Trial Data for Avapritinib in Patients with Systemic Mastocytosis at 24th EHA Congress
June 14, 2019
Blueprint Medicines Submits New Drug Application to U.S. Food and Drug Administration for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST
June 14, 2019
Kura Oncology Announces Positive Phase 2 Trial of Tipifarnib in Peripheral T-Cell Lymphoma
June 04, 2019
Bayer and Arvinas to Collaborate on Human PROTAC® Therapies and Launch a Separate Joint Venture to Develop Agricultural PROTAC® Applications
June 03, 2019
Blueprint Medicines’ Highly Selective RET Inhibitor BLU-667 Shows Durable Anti-Tumor Activity in Patients with RET-Altered Cancers in Updated ARROW Trial Data Presented at ASCO 2019
May 29, 2019
ARVINAS RECEIVES FAST TRACK DESIGNATION FOR ITS TARGETED PROTEIN DEGRADER ARV-110 AS A TREATMENT FOR MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
May 22, 2019
IDEAYA Announces Pricing of Initial Public Offering
May 16, 2019
Blueprint Medicines Announces Data Presentations at ASCO and EHA Meetings from Registration-Enabling Clinical Trials of Avapritinib and BLU-667 Across Multiple Patient Populations
May 08, 2019
IDEAYA Receives Authorization to Proceed with Phase 1/2 Tissue-Type Agnostic Basket Trial to Treat Patients with Tumors Harboring GNAQ/11 Mutations and PKC Fusions
April 30, 2019
Vividion Therapeutics Announces Oversubscribed $82 Million Series B Financing
April 18, 2019
Arrakis Therapeutics Announces $75 Million Series B Financing To Advance a New Class of Small-Molecule Medicines Targeting RNA
April 08, 2019
Neon Therapeutics Announces Completion of Enrollment in Phase 1b NT-002 Clinical Trial of NEO-PV-01 in Metastatic Non-Small Cell Lung Cancer
April 02, 2019
ARVINAS STRENGTHENS MANAGEMENT TEAM WITH INTERNAL APPOINTMENTS OF ANDY CREW, PH.D. AS CHIEF TECHNOLOGY OFFICER AND IAN TAYLOR, PH.D. AS CHIEF SCIENTIFIC OFFICER
April 02, 2019
Kura Oncology Identifies Farnesylated Proteins Associated with CXCL12 Expression, Potential Biomarker of Clinical Benefit from Tipifarnib in Lymphoma Indications
April 01, 2019
Turning Point Therapeutics’ Kinase Inhibitors Show High Potency Against Targeted Oncogene Drivers And Their Mutations
March 31, 2019
Neon Therapeutics Presents Updated Data from Ongoing Phase 1b NT-001 Clinical Trial of Personal Neoantigen Vaccine NEO-PV-01 at AACR 2019 Annual Meeting
March 25, 2019
Turning Point Therapeutics Appoints Jim Mazzola To Lead Corporate Communication And Investor Relations
March 20, 2019
Protein-slaying drugs could be the next blockbuster therapies
March 06, 2019
First targeted protein degrader hits the clinic
March 05, 2019
Kura Oncology Announces FDA Clearance of Investigational New Drug Application for Menin-MLL Inhibitor KO-539
February 19, 2019
Autolus Therapeutics Announces Updated Results from Ongoing CARPALL Trial of Pediatric Acute Lymphoblastic Leukemia Presented at the EHA 1st European CAR T Cell Meeting in Paris
February 13, 2019
IDEAYA Biosciences appoints Leading Cancer Researchers Frank McCormick, Ph.D., FRS, and William Sellers, M.D., to Scientific Advisory Board
January 18, 2019
Kura Oncology Reports Clinical Activity of Tipifarnib in Subsets of Pancreatic Cancer Associated with High CXCL12 Expression
January 04, 2019
ARVINAS RECEIVES AUTHORIZATION TO PROCEED FOR ITS IND APPLICATION FOR PROTAC™ THERAPY TO TREAT PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
January 04, 2019
Blueprint Medicines Announces “2020 Blueprint” Global Business Strategy and Outlines Key Corporate Goals
December 26, 2018
TRACON Pharmaceuticals Presents Positive Top-Line Clinical Data From Dose Escalation Portion Of Phase 1 Trial Of TRC105 And Opdivo® For Treatment Of Non-Small Cell Lung Cancer
December 21, 2018
TRACON Pharmaceuticals Announces Top-Line Data From Phase 2 TRAXAR Clinical Trial In Renal Cell Carcinoma
December 07, 2018
ARVINAS PRESENTS PRECLINICAL DATA ON PROTEIN DEGRADER, ARV-471, AT THE 2018 SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS)
December 06, 2018
Neon Therapeutics and Apexigen Announce First Patient Dosed in Neon’s NT-003 Phase 1b Combination Trial of NEO-PV-01 in Metastatic Melanoma
December 02, 2018
Autolus Therapeutics Presents Initial AUTO3 Clinical Data from Phase 1/2 Clinical Trials in B cell Malignancies at the 60th ASH Annual Meeting
December 02, 2018
Kura Oncology Announces Proof of Concept in Angioimmunoblastic T-Cell Lymphoma, Validation of CXCL12 as a Therapeutic Target of Tipifarnib in Peripheral T-Cell Lymphoma
December 02, 2018
Blueprint Medicines Announces Updated Results from Ongoing EXPLORER Clinical Trial of Avapritinib Demonstrating Broad Clinical Activity and Significant Symptom Reductions in Patients with Systemic Mastocytosis
December 01, 2018
Autolus Therapeutics Announces Update on its Novel CAR T Cell Program for Peripheral T Cell Lymphoma (PTCL)
November 29, 2018
TRACON Pharmaceuticals And I-Mab Biopharma Announce Strategic Partnerships For Multiple Immuno-Oncology Programs
November 28, 2018
Kura Oncology Announces New Patent for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma
November 15, 2018
Blueprint Medicines Announces Updated NAVIGATOR Trial Results in Patients with Advanced Gastrointestinal Stromal Tumors Supporting Development of Avapritinib Across All Lines of Therapy
November 09, 2018
Neon Therapeutics Presents Updated Data at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting
November 08, 2018
Kura Oncology Adds Commercial Veteran Mary Szela to Board of Directors
November 08, 2018
Neon Therapeutics Appoints Industry Veteran Robert Bazemore to its Board of Directors
November 01, 2018
Kura Oncology Announces Upcoming Presentations at ASH Annual Meeting
October 23, 2018
IDEAYA Licenses Phase 1 Compound LXS196 For The Treatment Of Cancers With GNAQ And GNA11 Mutations
October 22, 2018
Kura Oncology Presents Update on Positive Phase 2 Trial of Tipifarnib in HRAS Mutant HNSCC and Preliminary Results in HRAS Mutant SCC
October 16, 2018
REVOLUTION Medicines Acquires Warp Drive Bio to Expand Drug Discovery Portfolio Focused on Frontier Oncology Targets
October 09, 2018
REVOLUTION Medicines Announces First Patient Dosed with RMC-4630 in Phase 1 Clinical Study in Patients with Advanced Solid Tumors
October 06, 2018
Blueprint Medicines Announces Updated Data from Phase 1 ARROW Clinical Trial Showing Broad, Durable Activity of BLU-667 in Advanced RET-Altered Medullary and Papillary Thyroid Cancers
October 03, 2018
Neon Therapeutics to Present Data from Ongoing Phase 1b NT-001 Clinical Trial at the European Society for Medical Oncology 2018 Congress
October 01, 2018
Blueprint Medicines Presents Foundational Preclinical Data Supporting the Development of BLU-782, a Highly Selective ALK2 Inhibitor, for the Treatment of Patients with Fibrodysplasia Ossificans Progressiva
September 26, 2018
Blueprint Medicines Announces Proof-of-Concept Data Showing Combination of BLU-667 and Osimertinib Overcame Treatment Resistance in Two Patients with EGFR-Mutant, Non-Small Cell Lung Cancer and an Acquired RET Fusion
September 26, 2018
ARVINAS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING
September 10, 2018
TRACON Pharmaceuticals Announces Publication Of Phase 1b Results For TRC105 In Combination With Inlyta® In Patients With Advanced Or Metastatic RCC
August 21, 2018
Neon Therapeutics Appoints Jolie M. Siegel as General Counsel
August 08, 2018
TRACON Pharmaceuticals Reports Second Quarter 2018 Financial Results And Provides Corporate Update
August 06, 2018
Neon Therapeutics Reports Second Quarter 2018 Financial Results and Recent Business Highlights
August 06, 2018
Kura Oncology Reports Second Quarter 2018 Financial Results and Provides Corporate Update
August 01, 2018
TRACON To Report Second Quarter 2018 Company Highlights And Financial Results On August 8, 2018
August 01, 2018
Blueprint Medicines to Present at Upcoming Investor Conferences in August
August 01, 2018
Blueprint Medicines Reports Second Quarter 2018 Financial Results
July 31, 2018
Kura Oncology Appoints Marc Grasso, M.D., as Chief Financial Officer and Chief Business Officer
July 30, 2018
Kura Oncology to Report Second Quarter 2018 Financial Results
July 25, 2018
Blueprint Medicines to Report Second Quarter 2018 Financial Results on Wednesday, August 1, 2018
July 18, 2018
Sanofi and REVOLUTION Medicines Launch Global Partnership to Develop Potential First-in-Class Targeted Treatments for Multiple Cancers
July 02, 2018
Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
June 29, 2018
Neon Therapeutics Announces Closing of Initial Public Offering
June 28, 2018
Kura Oncology Announces Pricing of $67 Million Public Offering of Common Stock
June 27, 2018
Kura Oncology Announces Commencement of Public Offering of Common Stock
June 26, 2018
Autolus Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares
June 26, 2018
Neon Therapeutics Announces Pricing of Initial Public Offering
June 21, 2018
Blueprint Medicines Initiates VOYAGER Phase 3 Clinical Trial of Avapritinib in Patients with Advanced Gastrointestinal Stromal Tumors
June 20, 2018
Kura Oncology Appoints Chief Operating Officer, Expands Clinical Development Team as Company Prepares for First Registration-Directed Trial
June 15, 2018
Blueprint Medicines Announces Updated Data from Ongoing Phase 1 EXPLORER Clinical Trial of Avapritinib in Patients with Advanced Systemic Mastocytosis Showing Profound and Durable Clinical Activity
June 13, 2018
TRACON Announces Presentation Of Preclinical Data From Studies Of TRC105 In Combination With A PD-1 Antibody In Murine Models Of Colorectal Cancer
June 06, 2018
IDEAYA Biosciences to Present at the 2018 Jefferies Global Healthcare Conference
June 05, 2018
IDEAYA Biosciences Appoints Paul Stone, J.D., as Senior Vice President and General Counsel, Head of Operations and Mark Lackner, Ph.D. as Vice President, Head of Biomarkers and Synthetic Lethal Biology
June 04, 2018
Blueprint Medicines and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Avapritinib, BLU-554 and BLU-667 in Greater China
May 30, 2018
TRACON Pharmaceuticals Appoints Biotech Industry Veteran Mark Wiggins As Chief Business Officer
May 22, 2018
OncoDNA announces screening collaboration with Kura Oncology
May 08, 2018
Kura Oncology Reports First Quarter 2018 Financial Results and Provides Corporate Update
May 02, 2018
Kura Oncology Announces New Patent for Tipifarnib in Hematologic Malignancies
May 01, 2018
Kura Oncology to Report First Quarter 2018 Financial Results
April 25, 2018
Blueprint Medicines to Report First Quarter 2018 Financial Results on Wednesday, May 2, 2018
April 24, 2018
REVOLUTION Medicines Raises $56 Million in Series B Financing
April 15, 2018
Blueprint Medicines Announces Proof-of-Concept Data for Highly Selective RET Inhibitor BLU-667 from Phase 1 ARROW Clinical Trial in Patients with RET-Altered Solid Tumors
April 15, 2018
Blueprint Medicines Publication in Cancer Discovery Highlights Preclinical and Clinical Proof-of-Concept Data for Highly Selective RET Inhibitor BLU-667
April 09, 2018
TRACON Pharmaceuticals Announces Closing of Previously Announced Private Placement and Appointment of Ted Wang, Ph.D., of Puissance Capital Management, to Board of Directors
April 09, 2018
Kura Oncology Announces Upcoming Presentations at AACR Annual Meeting 2018
April 04, 2018
Arvinas Completes $55 Million Series C Financing to Advance Protein Degradation Platform
March 25, 2018
ARVINAS ANNOUNCES INITIATION OF PATIENT DOSING IN THE FIRST PHASE 1 CLINICAL TRIAL OF PROTAC™ PROTEIN DEGRADER, ARV-110
March 23, 2018
TRACON Pharmaceuticals Announces $38.7 Million Private Placement
March 15, 2018
IDEAYA Biosciences Raises $94 Million Crossover Series B Financing
March 14, 2018
Blueprint Medicines to Present Proof-of-Concept Data from Ongoing Phase 1 Clinical Trial of BLU-667 in Patients with RET-Altered Solid Tumors in a Clinical Trials Plenary Session at AACR Annual Meeting 2018
March 12, 2018
Kura Oncology Provides Regulatory Update on Tipifarnib and Reports Fourth Quarter and Full Year 2017 Financial Results
March 05, 2018
Kura Oncology to Report Fourth Quarter and Full Year 2017 Financial Results
February 28, 2018
TRACON Pharmaceuticals Reports Fourth Quarter And Year-End 2017 Financial Results And Provides Corporate Update
February 21, 2018
Blueprint Medicines Reports Fourth Quarter and Full Year 2017 Financial Results
February 15, 2018
Kura Oncology Provides Update on Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Cancer
February 14, 2018
Blueprint Medicines to Report Fourth Quarter and Full Year 2017 Financial Results on Wednesday, February 21, 2018
February 12, 2018
Santen Presents Phase I/II Data On DE-122 (Carotuximab) In Patients With Refractory Wet Age-Related Macular Degeneration
December 12, 2017
Neon Therapeutics Expands Board of Directors with Leading Experts in Cancer Drug Discovery and Corporate Finance
December 12, 2017
Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock
December 11, 2017
Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock
December 10, 2017
Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of Avapritinib (BLU-285) in Patients with Advanced Systemic Mastocytosis Showing Evidence of Strong Clinical Activity
December 07, 2017
Neon Therapeutics Announces Clinical Trial Collaboration with Merck
December 06, 2017
Neon Therapeutics Completes $106 Million Crossover Series B Financing
November 16, 2017
The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.
November 10, 2017
Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors Showing Strengthened Clinical Activity across Spectrum of KIT and PDGFRα Genotypes
November 06, 2017
STORM Therapeutics Strengthens Board with Appointment of Professor Paul Workman, President and CEO of The Institute of Cancer Research
November 01, 2017
Blueprint Medicines Announces Publication of BLU-285 Translational Data
November 01, 2017
Blueprint Medicines to Present Updated Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Systemic Mastocytosis in Plenary Scientific Session at 59th ASH Annual Meeting and Exposition
October 31, 2017
Blueprint Medicines Reports Third Quarter 2017 Financial Results
October 25, 2017
Blueprint Medicines to Report Third Quarter 2017 Financial Results on Tuesday, October 31, 2017
October 04, 2017
Neon Therapeutics Enters License Agreement with the Netherlands Cancer Institute for Neoantigen-based T Cell Therapeutics
July 10, 2017
CRISPR Therapeutics and Neon Therapeutics Enter Research Collaboration
June 05, 2017
Blueprint Medicines Announces New Phase 1 Clinical Data for BLU-285 in Advanced Gastrointestinal Stromal Tumors and Plans to Pursue Expedited Development in Patients with a PDGFRα D842V Mutation
April 26, 2017
Blueprint Medicines to Report First Quarter 2017 Financial Results on Wednesday, May 3, 2017
April 04, 2017
Blueprint Medicines Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares of Common Stock
March 30, 2017
Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock
March 29, 2017
Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock
March 27, 2017
Blueprint Medicines to Present on BLU-285 and BLU-554 at Upcoming Scientific Conferences
March 20, 2017
Blueprint Medicines Announces Enrollment of First Patient in Phase 1 Clinical Trial for BLU-667
March 09, 2017
Blueprint Medicines Reports Fourth Quarter and Full Year 2016 Financial Results
March 02, 2017
Blueprint Medicines to Report Fourth Quarter and Full Year 2016 Financial Results on Thursday, March 9, 2017
December 30, 2016
Biotech Jounce Therapeutics files for a $75 million IPO
December 07, 2016
Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock
December 06, 2016
Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock
December 04, 2016
Blueprint Medicines Announces Proof-of-Concept Data from Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Systemic Mastocytosis
November 30, 2016
Blueprint Medicines Announces Proof-of-Concept Data from Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors
November 28, 2016
Blueprint Medicines Announces Proof-of-Concept Data from Global Phase 1 Clinical Trial of BLU-554 in Patients with Advanced Hepatocellular Carcinoma
November 15, 2016
Blueprint Medicines to Present Preliminary Data from Ongoing Phase 1 Clinical Trials for BLU-285 and BLU-554 at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
November 15, 2016
Blueprint Medicines Announces Appointment of Marion Dorsch, Ph.D. as Chief Scientific Officer and the Transition of Christoph Lengauer, Ph.D., MBA, to a Newly Created Executive Vice President Role
September 13, 2016
Oxygen sensing – an essential process for survival
September 07, 2016
Jounce Therapeutics Initiates Phase 1/2 ICONIC Study of JTX­2011 in Patients with Advanced Solid Tumors
August 09, 2016
Blueprint Medicines Reports Second Quarter 2016 Financial Results
August 02, 2016
Blueprint Medicines to Report Second Quarter 2016 Financial Results on Tuesday, August 9, 2016
July 19, 2016
Jounce Therapeutics Announces Major Strategic Collaboration with Celgene Corporation to Develop Next-generation Immuno-oncology Therapies for Patients with Cancer
May 25, 2016
Jounce Therapeutics Appoints Barbara G. Duncan to its Board of Directors
May 10, 2016
Blueprint Medicines Reports First Quarter 2016 Financial Results
May 03, 2016
Blueprint Medicines to Report First Quarter 2016 Financial Results on Tuesday, May 10, 2016
April 29, 2016
Eminent cancer researchers elected to Royal Society Fellowship
April 25, 2016
MolecularMD has obtained CE Marking of a Diagnostic Assay Developed for a Daiichi Sankyo, Inc. Phase II Clinical Trial
April 17, 2016
Jounce Therapeutics Presents Data Highlighting Advances From Two Programs in its Immuno-Oncology Pipeline at the 2016 AACR Annual Meeting
March 21, 2016
TRACON Pharmaceuticals Reports Updated Positive Data on Ongoing Complete Response in Choriocarcinoma Patient Treated with TRC105
March 17, 2016
Jounce Therapeutics to Present Program Updates at AACR Annual Meeting 2016
March 15, 2016
Blueprint Medicines Announces Worldwide Collaboration to Accelerate and Expand its Development of Novel Medicines in the Field of Cancer Immunotherapy
March 11, 2016
Blueprint Medicines Reports Fourth Quarter and Full Year 2015 Financial Results
January 27, 2016
TRACON Pharmaceuticals Announces Initiation of TRC102 Phase 2 Clinical Trial in Glioblastoma
January 21, 2016
Jounce Therapeutics Appoints Perry Karsen to its Board of Directors
January 11, 2016
ImaginAb Appoints Benjamin Chen, Ph.D., as CEO, Joseph Limber as Chairman, and Forms Medical Advisory Board
January 05, 2016
Blueprint Medicines Strengthens Executive Leadership Team
December 17, 2015
Blueprint Medicines Added to NASDAQ Biotechnology Index
November 09, 2015
Blueprint Medicines Reports Third Quarter 2015 Financial Results
November 09, 2015
Blueprint Medicines Highlights Advances in Preclinical Discovery Efforts
November 09, 2015
Nextech Invest Portfolio Company Kura Oncology completes Public Offering at NASDAQ
November 07, 2015
Data from MacroGenics’ Ongoing Phase 1 Study of Enoblituzumab (MGA271) Presented at 30th Annual SITC Meeting 2015
November 03, 2015
Jounce Therapeutics Appoints Elizabeth Trehu, M.D., to Chief Medical Officer
October 22, 2015
MacroGenics and Merck to Collaborate on Immuno-Oncology Study Evaluating Margetuximab in Combination with KEYTRUDA(R) (pembrolizumab) for Advanced Gastric Cancer
October 12, 2015
Impacting Cancer
September 15, 2015
Jounce Therapeutics Appoints Kim Drapkin, CPA as Chief Financial Officer
September 10, 2015
Blueprint Medicines Receives FDA Authorization to Advance Novel Drug Candidate into Clinical Trial for Systemic Mastocytosis
September 01, 2015
Blueprint Medicines to Present Preclinical Data on BLU-554 and on Novel Drug Target at International Liver Cancer Association 9th Annual Conference
August 10, 2015
Blueprint Medicines Reports Second Quarter 2015 Financial Results and Provides Business Update
August 05, 2015
MacroGenics Provides Update on Corporate Progress and Second Quarter 2015 Financial Results
July 14, 2015
MacroGenics Announces Pricing of Public Offering of Common Stock
July 13, 2015
Blueprint Medicines Receives FDA Authorization to Proceed with Clinical Trials for Two Drug Candidates
June 22, 2015
Blueprint Medicines Debuts Preclinical Data for First-in-Class RET Drug Candidate
May 30, 2015
MacroGenics Presents Updated Data from Phase 1 Study of Margetuximab at ASCO Annual Meeting 2015
May 14, 2015
TRACON’s TRC105 Receives FDA Fast Track Designation
April 30, 2015
Nextech Invest Portfolio Company Blueprint Medicines Raises US$ 147 million in Upsized IPO on NASDAQ
April 25, 2015
TetraLogic Announces Publication of Two Papers Describing Birinapant’s Preclinical Activity in Chronic Hepatitis B
April 24, 2015
Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma
April 23, 2015
Jounce Therapeutics Secures $56 Million in Oversubscribed Series B Financing
April 21, 2015
Peloton Therapeutics Inc. Presents Promising Data on First Inhibitor of HIF-2α for Renal Cell Carcinoma at 2015 AACR Annual Meeting
April 19, 2015
Presentation Abstract
April 19, 2015
Blueprint Medicines Presents New Preclinical Data Demonstrating Significant AntiTumor Activity of BLU-285 in Treatment-Resistant GIST and on Novel Cancer Drug Targets
March 24, 2015
Blueprint Medicines Files Registration Statement for Proposed Initial Public Offering
March 03, 2015
Blueprint Medicines Announces Strategic Collaboration with Alexion to Advance Kinase Drug Candidates in Rare Genetic Disease
February 12, 2015
Blueprint Medicines Appoints Anthony Boral, M.D., Ph.D., as Senior Vice President, Clinical Development
January 29, 2015
TRACON Pharmaceuticals Announces Pricing of Initial Public Offering
December 30, 2014
Cancer biotech TRACON Pharmaceuticals files for a $58 million IPO
December 22, 2014
MacroGenics Enters Collaboration and License Agreement with Janssen to Develop MGD011 for Multiple B-Cell Malignancies
December 08, 2014
Blueprint Medicines Debuts Comprehensive Preclinical Data Set on First Selective Drug for Patients with Systemic Mastocytosis at 2014 American Society of Hematology Annual Meeting
December 01, 2014
TRACON Pharmaceuticals Initiates Randomized Phase 2 Clinical Trial of TRC105 in Patients with Renal Cell Carcinoma
November 24, 2014
Professor Paul Workman has been appointed as Chief Executive and President of The Institute of Cancer Research, London, on a permanent basis.
November 20, 2014
Blueprint Medicines Unveils New Drug Discovery Program for Patients with RET Fusions at 26th EORTC-NCI-AACR Symposium
November 12, 2014
Blueprint Medicines Secures $50 Million in Series C Financing
October 14, 2014
Nextech Invest Announces First Closing of Oncology Fund IV
October 06, 2014
Sunesis Announces Results From Pivotal Phase 3 VALOR Trial of Vosaroxin and Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia
September 29, 2014
MacroGenics and Takeda Enter Second Strategic Alliance to Develop Multiple Additional DART Therapeutics
September 24, 2014
TRACON Pharmaceuticals Announces Results From Clinical Trials of TRC105 in Patients With Ovarian Cancer to be Presented at the 2014 Annual Meeting of the European Society for Medical Oncology
September 22, 2014
TRACON Pharmaceuticals Completes $27 Million Financing and Expands Management Team and Board of Directors
September 19, 2014
First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines
September 10, 2014
Blueprint Medicines Discovers Novel Cancer Drug Targets
September 08, 2014
Blueprint Medicines Presents Positive Data on BLU-554 for Hepatocellular Carcinoma
September 04, 2014
TRACON Pharmaceuticals Initiates Phase 2 Clinical Trial of TRC105 in Patients with Soft Tissue Sarcoma
July 24, 2014
Blueprint Medicines Appoints Jeffrey Albers as Chief Executive Officer
June 28, 2014
Onkologie verspricht viele Chancen
June 09, 2014
TetraLogic Pharmaceuticals Announces Preclinical Data Indicating Birinapant’s Breadth of Activity in Models of Infectious Disease
May 27, 2014
MacroGenics and Takeda Enter Strategic Alliance to Develop DART for Treatment of Autoimmune Disorders
May 19, 2014
ImaginAb Selected as a Red Herring Top 100 North America Winner
May 06, 2014
MacroGenics Provides Update on Corporate Progress and First Quarter 2014 Financial Results
April 01, 2014
TetraLogic Pharmaceuticals Announces Publication of Preclinical Characterization of Birinapant
March 27, 2014
TetraLogic Pharmaceuticals to Present Data From Its SMAC-Mimetic Program at Upcoming AACR Annual Meeting 2014
March 24, 2014
Blueprint Medicines to Present on the First Isoform Selective FGFR4 Inhibitor at the AACR Annual Meeting 2014
March 24, 2014
Former CEO of Centrum Bank strengthens Nextech Invest’s global growth initiative
March 04, 2014
TRACON Pharmaceuticals Announces Agreement with Santen Pharmaceutical Co., Ltd. for the Development and Commercialization of TRC105 in Ophthalmology
February 27, 2014
Sunesis Announces Pricing of a $43.0 Million Public Offering of Common Stock and Warrants
February 20, 2014
MolecularMD to Develop Highly Sensitive Companion Diagnostic Test to Support CML Treatment Free Remission Clinical Trials
February 12, 2014
MacroGenics Completes Follow-on Offering of Common Stock ,Proceeds to fund clinical development of multiple assets
February 05, 2014
Professor Paul Workman receives prestigious Raymond Bourgine Award for cancer research
January 22, 2014
A Rising Biotech Market Offers Great Opportunities
January 07, 2014
Blueprint Medicines Announces $25 Million Series B Financing
December 12, 2013
TetraLogic Announces Pricing of Initial Public Offering of Common Stock
October 14, 2013
Nextech Invest Portfolio Company MacroGenics Starts Trading on NASDAQ
October 10, 2013
Nextech Invest Portfolio Company MacroGenics Starts Trading on NASDAQ
September 24, 2013
MacroGenics – 2013 Fierce 15
September 23, 2013
Fachkompetenz in der Onkologie
September 05, 2013
MacroGenics files paperwork for $60 million IPO
September 05, 2013
German Biotechnology: Where’s the Love?
August 20, 2013
MacroGenics to Receive $10 Million Milestone Payment from Servier for Dosing the First Patient in a Phase 1 Dose Expansion Trial of MGA271
August 12, 2013
MacroGenics Appoints Jon Wigginton, M.D., as Senior Vice President, Clinical Development
July 29, 2013
Cancer Research UK prize winners announced
June 13, 2013
Data and Safety Monitoring Board Recommends Continuation of Sunesis Pharmaceuticals’ VALOR Trial With no Change to Study Conduct
April 16, 2013
Molecular imaging as a de-risking tool: coming into focus?
April 07, 2013
Cancer Immunology Research
March 11, 2013
Innovative startups 2012
January 05, 2013
MacroGenics and Gilead Sciences Enter Strategic Alliance to Develop and Commercialize Four DART™ Products